

## Celyad appoints Graham Morrell as Vice-President of Investors Relations & Communication

---

**Mont-Saint-Guibert, Belgium** - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Graham K. Morrell as Vice-President of Investors Relations & Communication, effective as from 13<sup>th</sup> of June 2016.

Mr. Morrell joins Celyad with extensive experience in investor relations management and institutional equity trading. Prior to Celyad, Graham was Senior Vice President for The Trout Group/Trout Capital LLC where he was responsible for leading investor relation and capital market strategies for life science companies. Graham holds a B.A. in Government from Harvard University.

**Patrick Jeanmart, CFO of Celyad:** *"We are pleased to welcome Graham to our executive management team, where he brings over 15 years of expertise in financial markets and investor relations. Based on his strong experience in Investor Relations and his good knowledge of the biopharmaceutical industry, Graham will head the implementation of our Investor Relations strategy in the U.S."*

**Graham K. Morrell:** *"I am honored to be joining Celyad during this truly transformational period in its growth. I am excited to be part of an impressive team at Celyad and look forward to helping strengthen the company's relationship with the investment community."*

Graham will be based in Boston, USA and will report to Patrick Jeanmart, Chief Financial Officer.

\*\*\*END\*\*\*

## For more information, please contact:

### For Europe : Consilium Strategic Communications

Amber Fennell, Chris Gardner, Chris Welsh, and Laura Thornton - T: +44 (0)20 3709 5700 – [celyad@consilium-comms.com](mailto:celyad@consilium-comms.com)

---

### For France : NewCap

Pierre Laurent and Nicolas Mérieau - T: + 33(0)1 44 71 94 94 - [celyad@newcap.eu](mailto:celyad@newcap.eu)

---

### For Belgium : Comfi

Gunther De Backer: t.: +32 (0)2 290 90 90 – [gunther@comfi.be](mailto:gunther@comfi.be)

---

### Celyad

Christian Homsy, CEO and Patrick Jeanmart, CFO : T : +32 (0)10 39 41 00 [investors@celyad.com](mailto:investors@celyad.com)

---

To subscribe to Celyad's newsletter, visit [www.celyad.com](http://www.celyad.com)

 Follow us on Twitter [@CelyadSA](https://twitter.com/CelyadSA)

---

## About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKR-2 T-cell, entered a Phase I clinical trial in April 2015.

Celyad's ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad's American Depository Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD.

To learn more about Celyad, please visit [www.celyad.com](http://www.celyad.com)

## Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, including statements about the potential safety and feasibility of NKR-2 T-cell therapy and C-Cure and the clinical potential of the Company's technology platform generally and the timing of future clinical trials, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements.

In particular it should be noted that the safety data described in the release are preliminary in nature and the Phase 1 trial is not completed. There is limited data concerning safety and feasibility of NKR-2. These data may not continue for these subjects or be repeated or observed in ongoing or future studies involving our NKR-2 therapy, C-Cure or other product candidates. It is possible that safety issues or adverse events may arise in the future.

These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including risks associated with conducting clinical trials; the risk that safety, bioactivity, feasibility and/or efficacy demonstrated in earlier clinical or pre-clinical studies may not be replicated in subsequent studies; risk associated with the timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKR-2; risks associated with the satisfaction of regulatory and other requirements; risks associated with the actions of regulatory bodies and other governmental authorities; risks associated with obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; risks associated with competition from others developing products for similar uses; risks associated with our ability to manage operating expenses; and risks associated with our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. A further list and description of these risks, uncertainties and other risks can be found in the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on June 19, 2015 and future filings and reports by the Company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.



Press Release

14 June 2016

07:00 am CET

C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, NKR-2, C-Cath<sup>ez</sup><sup>™</sup>, Celyad, C-Cath<sup>ez</sup><sup>™</sup>, CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the Company.